HUMA Humacyte, Inc. - Common Stock
NASDAQ · Biotechnology close Oct 2, 2026
$0.52
· of 52w range
· above low
· to high
$0.5052w low
$2.5552w high
your badges
52W Range
$1–$3
Analyst Rating
BUY
Price Target
$2
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
HUMA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.52
52W Range
$1–$3
HUMA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
34.1%
Next Report
Nov 10, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 12, 2026 | $-0.16 | $-0.10 | -56.9% |
| March 31, 2026 | May 13, 2026 | $-0.09 | $-0.12 | 24.1% |
| Dec. 31, 2025 | $-0.13 | $-0.13 | 3.2% | |
| Sept. 30, 2025 | $-0.11 | $-0.16 | 31.9% | |
| June 30, 2025 | $-0.24 | $-0.16 | -45.5% | |
| March 31, 2025 | $0.28 | $-0.19 | 244.5% | |
| Dec. 31, 2024 | $-0.16 | $-0.26 | 37.3% |
Institutional owners (13F) 185 filers · $66.0M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
185
Value held
$66.0M
New positions
42
Exited positions
33
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 42 (+5 vs prior Q) | 33 (+18 vs prior Q) | 60 (+4 vs prior Q) | 38 (+7 vs prior Q) | +15.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $8,088,709 | 8,416,971 | 12.25% | Shares |
| ANTIPODES PARTNERS Ltd | $7,884,886 | 10,103,647 | 11.94% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $7,883,990 | 10,107,679 | 11.94% | Shares |
| Alyeska Investment Group, L.P. | $4,700,291 | 6,022,925 | 7.12% | Shares |
| Davidson Kempner Capital Management LP | $3,902,000 | 5,000,000 | 5.91% | Shares |
| BlackRock, Inc. | $3,777,079 | 4,839,929 | 5.72% | Shares |
| GREAT POINT PARTNERS LLC | $2,926,500 | 3,750,000 | 4.43% | Shares |
| UBS Group AG | $2,217,924 | 2,843,493 | 3.36% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $2,026,801 | 2,597,134 | 3.07% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,706,048 | 2,185,225 | 2.58% | Shares |
| MILLENNIUM MANAGEMENT LLC | $1,489,822 | 1,909,049 | 2.26% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,326,089 | 1,699,243 | 2.01% | Shares |
| CITADEL ADVISORS LLC | $1,126,411 | 1,443,376 | 1.71% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1,056,283 | 1,353,515 | 1.60% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $921,395 | 1,181,276 | 1.40% | Shares |
| LPL Financial LLC | $800,327 | 1,025,535 | 1.21% | Shares |
| Private Advisor Group, LLC | $753,156 | 965,091 | 1.14% | Shares |
| STATE STREET CORP | $657,516 | 842,537 | 1.00% | Shares |
| HBK INVESTMENTS L P | $616,516 | 790,000 | 0.93% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $544,284 | 697,800 | 0.82% | Put option |
| WEALTH EFFECTS LLC | $541,535 | 693,920 | 0.82% | Shares |
| Lion Point Capital, LP | $507,260 | 650,000 | 0.77% | Shares |
| LuminArx Capital Management LP | $507,260 | 650,000 | 0.77% | Shares |
| GOLDMAN SACHS GROUP INC | $457,723 | 586,524 | 0.69% | Shares |
| BANK OF AMERICA CORP /DE/ | $451,303 | 578,592 | 0.68% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $443,446 | 568,521 | 0.67% | Shares |
| JANE STREET GROUP, LLC | $431,249 | 552,600 | 0.65% | Call option |
| Woodline Partners LP | $390,654 | 500,582 | 0.59% | Shares |
| Ghisallo Capital Management LLC | $390,200 | 500,000 | 0.59% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $384,540 | 493,000 | 0.58% | Call option |
| NORTHERN TRUST CORP | $356,231 | 456,473 | 0.54% | Shares |
| Pamalican Asset Management Ltd | $341,000 | 200,000 | 0.52% | Shares |
| Aster Capital Management (DIFC) Ltd | $329,610 | 422,360 | 0.50% | Shares |
| Hudson Bay Capital Management LP | $292,650 | 375,000 | 0.44% | Shares |
| MORGAN STANLEY | $269,333 | 345,122 | 0.41% | Shares |
| CITADEL ADVISORS LLC | $235,213 | 301,400 | 0.36% | Call option |
| Scientech Research LLC | $221,636 | 284,003 | 0.34% | Shares |
| IEQ CAPITAL, LLC | $217,772 | 279,052 | 0.33% | Shares |
| LJI Wealth Management, LLC | $210,318 | 269,500 | 0.32% | Shares |
| Invesco Ltd. | $199,419 | 255,534 | 0.30% | Shares |
| NOMURA HOLDINGS INC | $187,296 | 240,000 | 0.28% | Call option |
| Stonepine Capital Management, LLC | $180,506 | 231,299 | 0.27% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $163,716 | 209,785 | 0.25% | Shares |
| United Asset Strategies, Inc. | $163,578 | 209,608 | 0.25% | Shares |
| Catalyst Funds Management Pty Ltd | $162,245 | 207,900 | 0.25% | Shares |
| MARSHALL WACE, LLP | $141,829 | 181,831 | 0.21% | Shares |
| TWO SIGMA ADVISERS, LP | $138,408 | 144,100 | 0.21% | Shares |
| Mariner, LLC | $136,566 | 174,975 | 0.21% | Shares |
| Schonfeld Strategic Advisors LLC | $126,142 | 161,639 | 0.19% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $124,864 | 160,000 | 0.19% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Fresenius Medical Care Holdings, Inc., Fresenius Medical Care AG ×6 filings | April 27, 2026 | 8.40% | Amendment | · | SEC |
| Laura E. Niklason, Brady W. Dougan ×10 filings | Nov. 20, 2024 | · | Initial filing | · | SEC |
| Dec. 1, 2023 | · | Initial filing | · | SEC | |
| Rajiv Shukla, AHAC Sponsor LLC | Sept. 25, 2020 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 23 insiders · 9 officers · 15 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Laura E Niklason | President, CEO and Director | Aug. 20, 2025 S | 0 | 0 | 0 | $0 |
| Dale A. Sander | CFO and Chief Corp. Dev. Off | May 18, 2026 S | 267,213 | 0 | 1 | $-41,298 |
| Heather Ledbetter Prichard | Chief Operating Officer | Jan. 21, 2025 A | 0 | 0 | 0 | $0 |
| Shamik J Parikh | Chief Medical Officer | May 18, 2026 S | 272,713 | 0 | 1 | $-41,298 |
| William John Scheessele | Chief Commercial Officer | April 14, 2025 P | 22,018 | 0 | 0 | $0 |
| Yang Cao | Chief Regulatory Officer | Jan. 21, 2025 A | · | 0 | 0 | $0 |
| Jeffrey Harold Lawson | Chief Surgical Officer | Aug. 26, 2021 A | 7,877 | 0 | 0 | $0 |
| William Edward Tente | Chief Regulatory Officer | Aug. 26, 2021 A | 52,519 | 0 | 0 | $0 |
| Kiernan Thomas Deangelis | Chief Medical Officer | Aug. 26, 2021 A | · | 0 | 0 | $0 |
| Keith Anthony Jones | Director | Sept. 14, 2026 P | 50,000 | 1 | 0 | $5,600 |
| Kathleen Sebelius | Director | May 19, 2026 P | 148,025 | 1 | 0 | $50,000 |
| Michael T. Constantino | Director | May 18, 2026 P | 43,950 | 1 | 0 | $9,790 |
| Brady W Dougan | Director | Aug. 20, 2025 S | 0 | 0 | 0 | $0 |
| John Philip Bamforth | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Charles Bruce Green | Director | June 12, 2025 A | 8,400 | 0 | 0 | $0 |
| Diane Seimetz | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Emery N. Brown | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Max N. Wallace | Director | June 12, 2025 A | 3,990 | 0 | 0 | $0 |
| Susan Richards Windham-Bannister | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Todd Pope | Director | June 12, 2025 A | · | 0 | 0 | $0 |
| Gordon M Binder | Director | May 15, 2024 P | 160,000 | 0 | 0 | $0 |
| Rajiv Shukla | Director | June 15, 2023 A | · | 0 | 0 | $0 |
| Ayabudge LLC | 10% owner | Aug. 21, 2023 S | 8,191,140 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBB · iShares Trust | 0.01% | 1,850,740 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.01% | 19,646 SH | Oct. 1, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.01% | 437,912 SH | Oct. 1, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 2,122,919 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 7,716,766 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.00% | 568,521 SH | Aug. 19, 2026 | Daily |
HUMA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 11 analysts
BUY
Median target
$1.25
+139.7%
3 27.3%
Strong Buy
6 54.5%
Buy
2 18.2%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
5 analysts · 2026-09-28Mean target $1.85 +254.7%
← Below all targets
Current price $0.52
Low$1.00
Mean$1.85
High$4.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| HUMA | · | · | · | · | · | · |
| TARA | $286M | -4.0 | · | · | -33.7% | · |
| NBP | $1.06B | -19.0 | · | · | -21.4% | · |
| NERV | $174M | -0.1 | · | · | 339.5% | · |
| TNXP | $200M | -1.1 | 29.8% | -946.2% | -60.0% | · |
| ABOS | $128M | -1.1 | · | · | -129.4% | · |
| KRRO | $75M | -0.6 | 181.5% | -1834.5% | -140.8% | · |
| PMVP | $67M | -0.8 | -40.5% | -1226.8% | -63.4% | · |
| OTLK | $57M | -0.6 | · | -4416.2% | 193.1% | 4.0% |
| RNA | $10.91B | -14.5 | 72.1% | -3650.4% | -47.5% | · |
| CBUS | · | -0.6 | -14.6% | -3492.3% | -223.0% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.